Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men

Journal of Infectious Diseases

Volumn 203, Issue 1, 2011, Pages 66-74

  Goldstone, Stephen ^a   Palefsky, Joel M ^b   Giuliano, Anna R ^c   Moreira Jr , Edson D ^d   Aranda, Carlos ^e   Jessen, Heiko ^f   Hillman, Richard J ^g   Ferris, Daron G ^h   Coutlee, Francois ⁱ   Liaw, Kai Li ^j   Marshall, J Brooke ^j   Zhang, Xuehong ^k   Vuocolo, Scott ^j   Barr, Eliav ^j   Haupt, Richard M ^j   Guris, Dalya ^j   Garner, Elizabeth I O ^j  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^f J2: Private Clinic for Infectious Diseases   (Germany)

^g UNIVERSITY OF SYDNEY   (Australia)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j MERCK RESEARCH LABORATORIES   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANAL CANAL; ANTIBODY BLOOD LEVEL; ARTICLE; AUSTRALIA; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SEROPREVALENCE; SEXUALITY; SMOKING CESSATION; VIRUS DETECTION; WART VIRUS;

EID: 79851500696     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq016     Document Type: Article

References (17)

1. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006; 194:1044-57. (Pubitemid 44547644)
2. Lu B, Wu Y, Nielson CM, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 2009; 199:362-71.
3. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495-503. (Pubitemid 28116159)
4. Van Der Snoek EM, Niesters HG, Mulder PG, van Doornum GJ, Osterhaus AD, Van Der Meijden WI. Human papillomavirus infection in men who have sex with men participating in a Dutch gay-cohort study. Sex Transm Dis 2003; 30:639-44. (Pubitemid 36959568)
5. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004; 190:2070-6. (Pubitemid 39636353)
6. Frisch M, Smith E, Grulich A, Johansen C. Cancer in a populationbased cohort of men and women in registered homosexual partnerships. Am J Epidemiol 2003; 157:966-72. (Pubitemid 36628799)
7. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19:1407-14. (Pubitemid 41800677)
8. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-10.
9. Giuliano AR, Palefsky JM, Goldstone S, et al. The efficacy of quadrivalent HPV vaccine in preventing HPV 6/11/16/18-related external genital disease and anogenital infection in young men. New Engl J Med 2010. Submitted.
10. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51.
11. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. ClinDiagn Lab Immunol 2003; 10:108-15.
12. Vardas E, Giuliano AR, Goldstone S, et al. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis 2011; 203:58-65.
13. Henry MR. The Bethesda System 2001: an update of new terminology for gynecologic cytology. Clin Lab Med 2003; 23:585-603.
14. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183:383-91. (Pubitemid 32105597)
15. Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis 2008; 197:1676-84. (Pubitemid 351919631)
16. Simatherai D, Bradshaw CS, Fairley CK, Bush M, Heley S, Chen MY. What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 2009; 85:148-9.
17. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006; 6:21-31. (Pubitemid 41831374)